Bharati Vidyapeeth Deemed to be University Medical College, Pune, Maharashtra; Department of Pathology, Maulana Azad Medical College, New Delhi, India.
Department of Pathology, Maulana Azad Medical College, New Delhi, India.
Indian J Pathol Microbiol. 2021 Oct-Dec;64(4):687-692. doi: 10.4103/IJPM.IJPM_248_20.
Gall bladder carcinoma (GBC) is a multi-factorial disease, involving multiple genetic alterations. The present pilot study aims to explore some of the molecular pathways, by studying immunohistochemical (IHC) expression of biomarkers (HER2/neu, KRAS, and VEGF) in GBC with their correlation with various clinicopathological parameters.
To study the expression of prognostic biomarkers (HER2/neu, KRAS and VEGF-A) in GBC and their correlation with clinico-morphological parameters. Materials and.
This prospective study was conducted over a period of 2 years. The study group included tissue of GBC (29) reported as malignant on histopathology and cholecystitis as a control group (29) for histopathological evaluation and IHC expression of above markers.
HER2/neu was expressed in 27.5% cases, and KRAS in 51.6%; however, both showed no association with tumor type, stage and grade. No association was found in KRAS expression and dysplasia. Vascular Endothelial Growth Factor - A (VEGF-A) was expressed in 86.1% cases, of which strong positivity was seen in 48.27%; it showed significant association with tumor stage (P value-0.027, Fishers' exact test), hence possibly suggesting its role in tumor progression; though no association was found in VEGF expression with tumor type and grade. No significant association was seen with vascular and tumor invasion also.
The results suggest that the VEGF-A expression may be used as a potential prognostic biomarker in GBC.
胆囊癌（GBC）是一种多因素疾病，涉及多种基因改变。本初步研究旨在通过研究胆囊癌中生物标志物（HER2/neu、KRAS 和 VEGF）的免疫组织化学（IHC）表达，并将其与各种临床病理参数相关联，来探讨一些分子途径。
研究 GBC 中预后生物标志物（HER2/neu、KRAS 和 VEGF-A）的表达及其与临床形态学参数的相关性。材料和方法：本前瞻性研究在 2 年内进行。研究组包括组织学报告为恶性的 GBC（29 例）和作为组织学评估和上述标志物免疫组化表达的对照组（29 例）。
HER2/neu 在 27.5%的病例中表达，KRAS 在 51.6%的病例中表达；然而，两者均与肿瘤类型、分期和分级无关。KRAS 表达与发育不良之间也没有关联。血管内皮生长因子-A（VEGF-A）在 86.1%的病例中表达，其中强阳性占 48.27%；它与肿瘤分期显著相关（P 值=0.027，Fisher 确切检验），因此可能提示其在肿瘤进展中的作用；尽管 VEGF 表达与肿瘤类型和分级无关。VEGF 表达与血管和肿瘤浸润也没有显著相关性。
结果表明，VEGF-A 表达可能可作为 GBC 的潜在预后生物标志物。
